The combination of ICIs and angiogenesis inhibitors is also being studied in several trials for HCC, such as durvalumab (anti-PD-L1) plus bevacizumab (NCT03847428) and CS1003 (anti-PD-1) plus lenvatinibin addition to the atezolizumab and bevacizumab combination, another approved combination for unresectable HCC is tremelimumab (anti-CTLA-4) combined with durvalumab (anti-PD-L1). Here, PDCD1 is linked to hepatocellular carcinoma.